FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and constitutes an isolated humanised anti-VSIG4 antibody or an antigen-binding fragment thereof with a certain structure. Invention also relates to a pharmaceutical composition containing said antibody.
EFFECT: possibility of effectively treating a VSIG4-associated disease.
30 cl, 42 dwg, 12 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| SPECIFIC TO MUCIN-1 POLYPEPTIDE AND ITS USE | 2021 |
|
RU2805840C1 |
| ANTIBODY SPECIFICALLY BINDING TO N-TERMINAL REGION OF LYSYL-TRNA-SYNTHETASE EXPOSED ON CELL MEMBRANE | 2018 |
|
RU2739393C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIBODY SPECIFICALLY BINDING WITH THE N-TERMINAL OF LYSYL-TRNA SYNTHETASE AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY CELL MIGRATION | 2018 |
|
RU2749591C1 |
| ANTI-CEACAM1 ANTIBODY AND ITS APPLICATION | 2018 |
|
RU2754876C2 |
| NEW MODIFIED IMMUNOGLOBULIN Fc-FRAGMENT FUNCTION PROTEIN AND ITS USE | 2020 |
|
RU2800919C2 |
| NEW ANTI-C-MET-ANTIBODY AND APPLICATION THEREOF | 2018 |
|
RU2751720C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| CANCER-RELATED IMMUNOSUPPRESSION INHIBITOR | 2018 |
|
RU2805232C2 |
